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Introduction
According to present WHO data, the high incidence rate 
of diseases is mainly due to the increasing rate of environ-
mental stress: air, soil, water pollution, etc. [1-3]. The impact 
of anthropological and emergency factors (SO2, H2SO4, NO, 
CO, CO2, electromagnetic radiation, etc.) on the human 
body leads to chronic toxicity and eco-endotoxicosis [2-4]. 
Eco-endotoxicosis might increase the risks for coronary 
heart disease (CHD) and myocardial hypoxia, as well as re-
duce tissue resistance, aggravate blood and lymph rheology, 
and interferes with microcirculation. All these factors might 
result in extensive myocardial damage [1, 4], followed by 
heart failure (HF), abnormal heart rate (HR) and sudden 
coronary death in myocardial infarction (MI) [1, 3]. There-
fore, new methods are currently being in search to reduce 
the level of average peptide molecular weight (PMW), as 
well as prevent or reduce the occurrence of various compli-
cations in early stages of MI [2, 3, 7, 12, 13]. Thrombolytic 
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Abstract
Background: The purpose of this study was to assess the effectiveness of the combined use of high doses of heparin, propranolol and  monopril with 
percutaneous coronary intervention (PCI) on eco-endotoxicosis, systolic blood pressure, diastolic blood pressure, heart rate (HR), cardiodynamics and 
on the clinical course in acute myocardial infarction (AMI) among patients working in environmentally unfriendly conditions.
Material and methods: The study was conducted on 42 patients, aged 30 to 70 years (56.7 ± 1.20 years) with acute coronary syndrome (ACS), who were 
assessed for the anterior Q wave MI and ST segment elevation MI. Of 42 patients, 21 were treated with monopril, propranolol with heparin and PCI 
(group 1); and 21 patients underwent only PCI (group 2). The degree of eco-endotoxicosis in blood was studied in both groups, whereas the echocardiography 
and Doppler echocardiography were used to determine the end-systolic volume (ESV), end-diastolic volume (EDV), left ventricular ejection fraction 
(LV EF), local LV contractile dysfunction, local contractile dysfunction index (LCDI), restenosis via a repeated coronary angiography, echographic study 
of ST segment elevation and of repeated anginal pain. 
Results: Patients treated with monopril with propranolol and heparin with PCI exhibited a stabilization of central hemodynamic indices, by a decrease 
in ESV, EDV, LCDI, and the degree of eco-endotoxicosis, as well as an improvement of LV systolic function by an increased EF. However, one patient 
from this group had an acute heart failure (AHF) on the 3rd day, whereas one patient experienced a MI relapse. The group of patients who underwent 
only PCI, revealed 3 cases of MI recurrence, 3 cases of restenosis, 2 cases of AHF and 2 patients died.
Conclusions: The combined use of drug and PCI therapy in acute coronary syndrome might lead to positive prognostic outcomes, rather than a separate 
PCI approach.
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therapy and angioplasty (percutaneous coronary interven-
tion – PCI) of the impaired coronary vessel have recently 
been used to reduce complications in the early MI stages [1, 
5]. Therefore, there is a great demand in searching for new 
methods to prevent and decrease the occurrence of various 
complications in early MI [5–9]. Thrombolytic therapy and 
angioplasty (percutaneous coronary intervention – PCI) 
of the impaired coronary vessel have recently been used 
to reduce complications in the early MI [5, 7, 8]. However, 
there are evidences that every third patient develops a re-
current myocardial infarction on already the first day after 
the thrombolytic therapy has been carried out  [5, 9, 10], 
followed by infarction-related coronary artery restenosis 
[5, 10, 11]. Moreover, the mechanical reperfusion in early 
myocardial infarction might increase the incidence of ad-
verse outcomes [1, 11]. Thus, the effectiveness and safety of 
a combined therapeutic approach are still being discussed 
among specialists and there is no consensus upon this is-
sue [5, 7, 10, 12]. At the same time, the combined use of 
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thrombolytics, anticoagulants, β-blockers, angiotensin con-
verting-enzyme inhibitors (ACE inhibitors) and PCI, which 
play a significant role in eco-endotoxicosis among patients 
with acute myocardial infarction, working in ecologically 
unfriendly conditions is still neither fully understood nor 
sufficient attention is paid [1, 4, 8]. Based on the latest spe-
cialized literature data, this study was conducted on the 
effectiveness of a combined use of high doses of heparin, 
propranolol , monopril and PCI on systolic blood pressure 
(SBP), diastolic blood pressure (DBP), heart rate (HR), car-
diodynamics and the clinical course of acute MI associated 
with eco-endotoxicosis, among patients exposed to ecologi-
cally unfriendly working conditions.
Material and methods
The study was conducted on 42 patients aged 30 to 70 
years (56.7 ± 1.20 years), presenting with acute coronary 
syndrome (ACS): the anterior Q-wave myocardial infarction 
and ST-segment elevation acute myocardial infarction were 
assessed. The study included 35 (83.3%) men and 7 (33.3%) 
women. The patients were randomly divided into 2 groups 
of 21 subjects each. The 1st group was administered propra-
ponol, heparin and monopril combined with PCI, whereas 
the 2nd group underwent PCI only. All patients worked in 
environmentally unfriendly conditions and were in contact 
with anthropological-emergency factors (SH2, SO2, H2SO4, 
NO, CO, CO2), electromagnetic radiation, etc. (tab. 1).
Both groups were assessed for the clinical course of the 
disease including SBP, DBP, heart rate, the early restenosis, 
recurrent myocardial infarction, acute heart failure (ACF) 
and mortality rate during the follow-up period. Addition-
ally, ACF was determined according to the Killip classifi-
cation over the last 7 days. The echocardiographic study of 
heart hemodynamics was carried out via SSD-2 (Aloka. Co., 
Ltd. Tokyo, Japan). The end-systolic volume (ESV), end-
diastolic volume( EDV), local contractile dysfunction index 
(LCDI), left ventricular ejection fraction (LV EF), restenosis 
via a repeated coronary angiography, echocardiographic as-
sessment of ST segment elevation and of recurrent anginal 
chest pains were determined. Monopril was administered 
over the first 3 days, 2.5 mg once daily in the morning, then 
5 mg / day over 10 days and 10 mg /day on the following 
days of MI.  5 mg of 0.1% propranolol were injected intrave-
nously within 5 minutes, followed by a 0.02 mg / kg / min IV 
dosage, 20-25 drops/minute, 4 times/day. Afterwards, the 
patients were given a dose of 80 to 120 mg /day per oral.  The 
1st group of patients used heparin: 20.000 units were first 
administered intravenously, concomitantly with the thera-
peutic dose of 10.000 units subcutaneously, followed by a 
6-hour administration interval on the 1st day, then 10.000 
IU on the 2nd-3rd days – every 8 hours, 10.000 IU on the 
4th-5th days – every 12 hours, 10.000 IU on the 6th day – 
once a day, followed by warfarin anticoagulant, 1 tablet – 2 
times/ day and a daily dose of 300 mg aspirin. The patients 
from the 2nd group underwent PCI and were administered 
300 mg of aspirin per day.
The obtained data was statistically processed by using 
the “Statistics 6.0” software program. The M values, their 
standard errors (m) and a 95% confidence interval were es-
timated. The study applied both the non-parametric Mann-
Whitney U test criterion and the Fisher’s exact test criterion. 
The difference was considered statistically significant with 
P <0.05.
Results
The analysis of environmental endotoxicosis-related 
SBP, DBP, and heart rate hemodynamic parameters, which 
were expressed by a higher level of PMW both in the group 
of patients treated with heparin, monopril and propranolol 
and PCI, as well as in PCI-treated subjects at the time of 
their hospital admission, showed no statistically significant 
difference (p> 0.05). The groups included those patients 
Table 1
Characteristics of patients working in environmentally unfriendly conditions
Environmentally stressful 
Conditions
(n=42)
Monopril + propranolol + heparin 
(n=21)
PCI  (n=21)
Number of 
patients
Work experience (years) Number of patients Work experience (years)
1. Machine engineering 4 10.20±2.35 4 10.31±3.10
2. Oil and gas processing industry 6 10.40±6.30 5 10.20±2.20
3. Chemical plant 4 10.56±4.60 3 10.49±3.0
4. Motor vehicle repair workshops 5 10.40±2.30 6 10.23±2.10
5. “Electroterm” plant 2 10.05±1.40 3 10.50±2.10
Total 21 10.31±3.30 21 10.23±2.60
Admission period 1-5 h 1-5 h
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who suffered mainly of hyper- and eukinetic hemodynamic 
variants (tab. 2.)
A significantly low level of PMW was recorded in pa-
tients from the 1st group, over 12 hours, viz. from 0.58 ± 
0.03 to 0.29 ± 0.01 units (p <0.001). A reduction in blood 
pressure was also registered, ranging between 138.0 ± 2.3 
/ 86.7 ± 1.3- to 123.0 ± 2.3 / 78.7 ± 1.7 mm Hg and which 
dropped up to 118.0 ± 1.8 / 75.9 ± 3.2 mm Hg until the 
end of the study (p> 0.001). Three patients from this group 
exhibited high level of PMW, though the blood pressure 
showed a decreasing tendency (up to 100/60 mm Hg). After 
the treatment, the level of PMW rapidly decreased (0.24 ± 
0.11 unit), whereas blood pressure increased up to 115/65 
mm Hg.  PCI contributed to a slight decrease in PMW and 
blood pressure. The level of PMW decreased from 0.59 ± 
0.6 to 0.56 ± 0.04 units, within 24 hours (p> 0.05), whereas 
blood pressure revealed 124.8 ± 3.4 / 74.00 ± 2.40 mm Hg, 
and 118.0 ± 1.7 / 75.1 ± 1.6 mm Hg on the 7th day (p <0.001). 
Changes of central hemodynamics and PMW during the 
treatment have been presented in table 2 (p> 0.05).
A significant decrease in heart rate among the 1st group 
patients was recorded over 24 hours, viz. from 100.0 ± 1.2 to 
75.20 ± 1.40 beats/ minute, thus being of 74.10 ± 1.9 beats /
minute at the end of the study. No heart rate decrease was 
registered in the 2nd group over 24 hours. However, it re-
duced up to 75.30 ± 2.1 beats/ minute within 72 hours.
The changes in the left ventricular (LV) function indices 
during the study are presented in table 2. The 1st group re-
vealed a progressively decreasing EDV that was statistically 
significant difference in both the index before the treatment 
for MI (p <0.001), and the study results obtained in the 2nd 
group (p <0.01). Patients treated with just PCI also showed 
a decrease in EDV.  84% of patients from the 1st group and 
75% of patients from the 2nd group showed a reduced LV 
EDV. 16% of patients of the 1st group and 25% of the 2nd 
group exhibited no decrease in both EDV index and its dy-
namics.
LV ESV in both the 1st group and the 2nd group de-
creased by 43.3% and 32.9% of patients, respectively, with a 
significant difference of p <0.01.
Indicators of the LV systolic function revealed no diffe-
rence between groups (p <0.005). By the end of the 1st day 
and on the 7th day of the follow-up period, patients from 
the 1st group showed an increased EF (45.40 ± 2.5% and 
61.91 ± 1.12%, respectively), which differed from the indi-
cators of the 2nd group (45.90 ± 2.10% and 54.31 ± 1.11%). 
A decrease in the LV contractile function was recorded in 2 
patients (9.5%) of the 1st group and in 10 patients (38.1%) 
of the 2nd group.
The values of LV LCDI were also different. Following a 
significant decrease in both the volume of myocardial dete-
rioration and the severity degree of myocardial asynergy in 
patients from the 1st group, LV LCDI also exhibited lower 
values (1.88 ± 0.10- before treatment, and 0.81 ± 0.21 at the 
end of therapy).  The indicators of LV LCDI from the 2nd 
group decreased from 1.78 ± 0.13 to 0.90 ± 0.12. (p> 0.001). 
Thus, a significant decrease in LV LCDI was registered in 
97% of patients from the 1st group, and 57% of patients 
from the 2nd group                .
Table 2
The dynamic patterns of central hemodynamic, LV systolic function and APM indices (M ± m)
Indices
Monopril + propranolol + heparin + PCI (n = 21) PCI(n=21) Р1
P2
Time elapsed since the start of treatment
Before 
treatment
12 h 24 h 72 h 7 day
Before  
treatment
12 h 24 h 72 h 7 day
SBP
mm Hg
138,0±2,3
Р>0,05
123,0±2,3 126,0±1,6 125,2±1,6 118,0±1,8
140,4±2,2
Р>0,05
122,2±2,1 124,8±3,4 125,5±2,2 118,0±1,7
<0,001
>0,05
DBP
 mm Hg
86,7±1,3
Р>0,05
78,7±1,7 73,7±1,6 75,1±3,3 75,9±3,3
84,9±1,2
Р>0,05
65,0±1,0 74,00±2,4 72,4±1,3 75,1±1,6
=0,05
>0,05
PMW, IU
0,58±0,03
р>0,05
0,29±0,01 0,30±0,06 0,28±0,02 0,26±0,05
0,59±0,06
Р>005
0,56±0,04 0,54±0,03 0,49±0,03 0,46±0,02
<0,001
<0,01
HR
beats/min
100,0±2,4
Р>0, 05
88,6±2,80 75,20±1,40 76,72±2,1 74,10±1,90
98,6±3,10
P>0,05
96,50±2,2 96,19±2,00 75,32±2,10 75,30±2,10
<0,01
>0,05
ESV, ml
90,20±2,90
Р>0,05
70,23±2,31 65,90±2,42 53,2±2,61 51,5±2,60
89,33±2,6
Р> 0,05
78,5±2,31 75,20±2,42 68,20±2,1 65,10±2,4
<0,001 
<0,01
EDV, ml
165,10±2,90
Р>0,05
150,11±2,29 143,71±2,15 135,82±2,17 134,76±2,1
164,18±2,00
Р>0,05
159,82±2,16 155,92±2,12 151,82±2,16 148,92±2,11
<0,001
<0,01
EF, %
45,40±2,5
Р>0,05
53,20±0,10 54,8,±1,41 60,81±1,17 61,91±1,12
44,80±2,30
Р>0,05
45,73±1,61 48,82±1,53 52,71±1,47 54,31±1,11
<0,001
<0,01
LCDI
1,88± 0,10 
Р>0,05
1,48± 0,23 1,35± 0,30 0,81± 0,17 0,81± 0,21
1,78± 0,13 
Р>0,05
1,73 ±0,17 1,52±0,15 0,87 ±0,12 0,90 ±0,13 < 0,01
Note: P – initial statistically significant difference; P1- statistically significant difference between initial and final results; Р2 – statistically 
significant difference of the final study results between the two groups.
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There were no significant differences in the clinical 
condition of patients on the 1st day. Acute heart failure was 
found in 2 patients from the 2nd group. One patient from 
the 1st group developed AHF on the 7th day. No resteno-
sis, MI recurrence, and mortality cases were registered.
The group of patients, undergoing only PCI (the 2nd 
group) included 2 (9.5%) cases of recurrent MI; 4 patients 
developed restenosis, according to the repeated coronary 
angiography data; and 2 (9.5%) patients died.  One patient 
died in the first 12 hours of PCI, the other one over 72 
hours after the restenosis onset.
Therefore, the combined drug therapy and PCI used 
for revascularization of the coronary arteries contributed 
to reduction of PMW, ESV, EDV, LV LCDI, as well as an in-
crease in LVEF, leading to a stabilization of  hemodynamic 
patients without a critical decrease in their blood pressure 
during the MI follow-up. The combined therapeutic ap-
proach prevented the development of coronary artery re-
stenosis, MI recurrence and mortality.
Discussion
Recently, the impact of environmental endotoxicosis 
has been highlighted regarding the hypoxia in peri-infarc-
tion area, myocardial metabolic impairment, and volume 
of myocardial deterioration, which leads to a change in LV 
systolic and diastolic function, as well as to the develop-
ment of various complications, which are proportional to 
the degree of environmental endotoxicosis and volume of 
myocardial involvement [1, 5- 7].
Currently, in order to determine the degree of environ-
mental endotoxicosis and the overall toxicity degree within 
the body, the PMW is being studied. The average peptide 
molecule is a marker of ischemic toxin, which impairs mi-
crocirculation, has a toxic effect on cardiomyocytes, and 
enhances the ischemic zone spread [1, 2]. Additionally, 
ecoendotoxicosis leads to an increase of PMW within the 
body, which inhibits the biosynthesis of proteins and the 
activity of a number of enzymes; oxidation and phosphor-
ylation are impaired, the synthesis of adenine and glucose 
metabolism are also inhibited. The treatment failure of 
ecoendotoxicosis-related myocardial infarction is mainly 
due to insufficient assessment of the severity degree of en-
dotoxemia associated with large doses of xenobiotic intake 
and anthropological-emergency factors, as well as the cat-
abolic products derived from the peri-infarction area [1].
Therefore, cardiologists are searching for new drugs 
and methods to prevent complications and improve prog-
nosis of AMI, which remains an urgent problem world-
wide [7, 8, 10]. Recently, thrombolytic therapy and angio-
plasty (PCI) of the infarct-related coronary artery have 
been used [3, 9-12]. However, arrhythmia and reperfusion 
syndrome might occur in patients following a thrombo-
lytic drug treatment. After drug reperfusion, remodeling 
of residual stenosis of the infarct-related coronary artery 
continues over the following week [9, 10]. There are evi-
dences that a standard PCI, performed immediately after 
a successful thrombolysis, might increase the frequency of 
complications, namely of AHF, restenosis, and recurrence 
of MI.
The combined drug and PCI treatment does not only 
restore the coronary blood flow but also helps to restore 
the local kinetics of myocardium segments in the peri-in-
farction area [9, 10], as well as to reduce the level of PMW 
[1, 4, 6]. The clinical data and our study results have re-
vealed that the use of β-adrenergic antagonists, particu-
larly of propranolol [1] and metoprolol succinate [7, 8] 
prior to PCI and coronary bypass surgery are considered 
essential for myocardial protection and thus, reducing the 
mortality rate in this category of patients [12]. However, 
due to the high BP and negative inotropic actions, they 
were applied in only 20-35% of patients with MI (1, 7, 8), 
which is contrary to specialized literature data [7, 8] and 
our experience. Thus, if reasonable contraindications are 
followed, the use of propranolol or metoprolol succinate 
does not result in negative outcomes [1, 7]. Moreover, pro-
pranolol, which improves lymphocirculation, also helps 
in removing the eco- and endotoxins out from the peri-
infarction area, and in reducing the systolic and diastolic 
LV functions.
In recent years, much attention has been paid to the 
use of ACE inhibitors in AMI, aimed at preventing the 
post infarct left ventricular remodeling and AHF [1, 2, 6]. 
Monopril (fosinopril) is the latest representative of ACE 
inhibitors, which is widely used in treatment of hyperten-
sion and congestive heart failure.
Thus, based on the research data, we concluded that 
the combined use of propranolol with monopril, heparin 
and PCI can reduce eco-endotoxicosis, restore myocardial 
blood flow, and improve LV systolic function. It also might 
increase the values of SI, CI, EF in patients, stabilize their 
SBP, DBP and heart rate. It also shows a more favorable 
impact on the clinical course of the disease.
Conclusions
1.  The group of patients working under environmen-
tally unfriendly conditions, and who underwent treatment 
with heparin, propranolol and monopril along with PCI 
at early stages of AMI, showed a rapid decrease in PMW, 
central hemodynamic stabilization, reduced systolic and 
diastolic LV functions, which might lead to early LV re-
modeling.
2. The combined use of heparin, propranolol and 
monopril together with PCI in the early stages of AMI 
patients, working in environmentally stressful conditions, 
revealed a more favorable clinical course of the disease; 
whereas MI recurrence, infarction-related coronary artery 
restenosis and mortality cases were not recorded.
3.  The group of patients, subjected to PCI only, exhib-
ited a high incidence of AHF, MI recurrence, infarction-
related coronary artery restenosis, and mortality cases.
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